Drugs / PF-08046031
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06799533 | May 2025 → Feb 2026 | cancer, melanoma | Pfizer | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PF-08046031 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06799533 ↗ |
| Route | Intravenous | “Given into the vein (IV; intravenous)” NCT06799533 ↗ |